Status:
COMPLETED
Gene Therapy for Achromatopsia (CNGA3)
Lead Sponsor:
MeiraGTx UK II Ltd
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Achromatopsia
Eligibility:
All Genders
3+ years
Phase:
PHASE1
PHASE2
Brief Summary
A clinical trial of adeno-associated virus vector (AAV) CNGA3 retinal gene therapy for patients with achromatopsia
Detailed Description
CNGA3 retinal gene therapy for patients with achromatopsia
Eligibility Criteria
Inclusion
- Are aged years or over
- Have achromatopsia confirmed by a retinal specialist investigator
Exclusion
- Are females who are pregnant or breastfeeding
- Have participated in another research study involving an investigational medicinal therapy for ocular disease within the last 6 months
- Have any other condition that the investigator considers makes them inappropriate for entry into the trial
Key Trial Info
Start Date :
August 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 10 2021
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03758404
Start Date
August 12 2019
End Date
June 10 2021
Last Update
December 1 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Kellogg Eye Center
Ann Arbor, Michigan, United States, 48105
2
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom, EC1V 2PD